Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study
In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI tr...
Ausführliche Beschreibung
Autor*in: |
Ángela Domínguez [verfasserIn] Núria Soldevila [verfasserIn] Diana Toledo [verfasserIn] Ignasi Parrón [verfasserIn] Joan-Pau Millet [verfasserIn] Irene Barrabeig [verfasserIn] Pere Godoy [verfasserIn] on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2023 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Vaccines - MDPI AG, 2013, 11(2023), 12, p 1800 |
---|---|
Übergeordnetes Werk: |
volume:11 ; year:2023 ; number:12, p 1800 |
Links: |
---|
DOI / URN: |
10.3390/vaccines11121800 |
---|
Katalog-ID: |
DOAJ098785818 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ098785818 | ||
003 | DE-627 | ||
005 | 20240414002229.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240414s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/vaccines11121800 |2 doi | |
035 | |a (DE-627)DOAJ098785818 | ||
035 | |a (DE-599)DOAJ76032033a6d14d41b529d7176567df09 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a Ángela Domínguez |e verfasserin |4 aut | |
245 | 1 | 0 | |a Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80.6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14.20; 95% CI 5.22–38.66) and exposure <6 h/day (aOR 7.32, 95% CI 2.48–21.64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0.22, 95% CI 0.08–0.64) and bacillus Calmette–Guerin vaccination (aOR 0.38, 95% CI 0.16–0.90). Crucial to LTBI treatment prescription is information on the contact’s duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels. | ||
650 | 4 | |a contact tracing | |
650 | 4 | |a tuberculosis | |
650 | 4 | |a latent TB infection | |
650 | 4 | |a treatment | |
650 | 4 | |a prescription | |
650 | 4 | |a prevention | |
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
700 | 0 | |a Núria Soldevila |e verfasserin |4 aut | |
700 | 0 | |a Diana Toledo |e verfasserin |4 aut | |
700 | 0 | |a Ignasi Parrón |e verfasserin |4 aut | |
700 | 0 | |a Joan-Pau Millet |e verfasserin |4 aut | |
700 | 0 | |a Irene Barrabeig |e verfasserin |4 aut | |
700 | 0 | |a Pere Godoy |e verfasserin |4 aut | |
700 | 0 | |a on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Vaccines |d MDPI AG, 2013 |g 11(2023), 12, p 1800 |w (DE-627)736559205 |w (DE-600)2703319-3 |x 2076393X |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2023 |g number:12, p 1800 |
856 | 4 | 0 | |u https://doi.org/10.3390/vaccines11121800 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/76032033a6d14d41b529d7176567df09 |z kostenfrei |
856 | 4 | 0 | |u https://www.mdpi.com/2076-393X/11/12/1800 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2076-393X |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 11 |j 2023 |e 12, p 1800 |
author_variant |
á d ád n s ns d t dt i p ip j p m jpm i b ib p g pg o b o t o t i c s w g obototicswg |
---|---|
matchkey_str |
article:2076393X:2023----::atrascaewttetetrsrpinoumnrtbruoicnatictlna0901pp |
hierarchy_sort_str |
2023 |
publishDate |
2023 |
allfields |
10.3390/vaccines11121800 doi (DE-627)DOAJ098785818 (DE-599)DOAJ76032033a6d14d41b529d7176567df09 DE-627 ger DE-627 rakwb eng Ángela Domínguez verfasserin aut Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80.6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14.20; 95% CI 5.22–38.66) and exposure <6 h/day (aOR 7.32, 95% CI 2.48–21.64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0.22, 95% CI 0.08–0.64) and bacillus Calmette–Guerin vaccination (aOR 0.38, 95% CI 0.16–0.90). Crucial to LTBI treatment prescription is information on the contact’s duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels. contact tracing tuberculosis latent TB infection treatment prescription prevention Medicine R Núria Soldevila verfasserin aut Diana Toledo verfasserin aut Ignasi Parrón verfasserin aut Joan-Pau Millet verfasserin aut Irene Barrabeig verfasserin aut Pere Godoy verfasserin aut on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group verfasserin aut In Vaccines MDPI AG, 2013 11(2023), 12, p 1800 (DE-627)736559205 (DE-600)2703319-3 2076393X nnns volume:11 year:2023 number:12, p 1800 https://doi.org/10.3390/vaccines11121800 kostenfrei https://doaj.org/article/76032033a6d14d41b529d7176567df09 kostenfrei https://www.mdpi.com/2076-393X/11/12/1800 kostenfrei https://doaj.org/toc/2076-393X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2023 12, p 1800 |
spelling |
10.3390/vaccines11121800 doi (DE-627)DOAJ098785818 (DE-599)DOAJ76032033a6d14d41b529d7176567df09 DE-627 ger DE-627 rakwb eng Ángela Domínguez verfasserin aut Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80.6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14.20; 95% CI 5.22–38.66) and exposure <6 h/day (aOR 7.32, 95% CI 2.48–21.64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0.22, 95% CI 0.08–0.64) and bacillus Calmette–Guerin vaccination (aOR 0.38, 95% CI 0.16–0.90). Crucial to LTBI treatment prescription is information on the contact’s duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels. contact tracing tuberculosis latent TB infection treatment prescription prevention Medicine R Núria Soldevila verfasserin aut Diana Toledo verfasserin aut Ignasi Parrón verfasserin aut Joan-Pau Millet verfasserin aut Irene Barrabeig verfasserin aut Pere Godoy verfasserin aut on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group verfasserin aut In Vaccines MDPI AG, 2013 11(2023), 12, p 1800 (DE-627)736559205 (DE-600)2703319-3 2076393X nnns volume:11 year:2023 number:12, p 1800 https://doi.org/10.3390/vaccines11121800 kostenfrei https://doaj.org/article/76032033a6d14d41b529d7176567df09 kostenfrei https://www.mdpi.com/2076-393X/11/12/1800 kostenfrei https://doaj.org/toc/2076-393X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2023 12, p 1800 |
allfields_unstemmed |
10.3390/vaccines11121800 doi (DE-627)DOAJ098785818 (DE-599)DOAJ76032033a6d14d41b529d7176567df09 DE-627 ger DE-627 rakwb eng Ángela Domínguez verfasserin aut Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80.6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14.20; 95% CI 5.22–38.66) and exposure <6 h/day (aOR 7.32, 95% CI 2.48–21.64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0.22, 95% CI 0.08–0.64) and bacillus Calmette–Guerin vaccination (aOR 0.38, 95% CI 0.16–0.90). Crucial to LTBI treatment prescription is information on the contact’s duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels. contact tracing tuberculosis latent TB infection treatment prescription prevention Medicine R Núria Soldevila verfasserin aut Diana Toledo verfasserin aut Ignasi Parrón verfasserin aut Joan-Pau Millet verfasserin aut Irene Barrabeig verfasserin aut Pere Godoy verfasserin aut on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group verfasserin aut In Vaccines MDPI AG, 2013 11(2023), 12, p 1800 (DE-627)736559205 (DE-600)2703319-3 2076393X nnns volume:11 year:2023 number:12, p 1800 https://doi.org/10.3390/vaccines11121800 kostenfrei https://doaj.org/article/76032033a6d14d41b529d7176567df09 kostenfrei https://www.mdpi.com/2076-393X/11/12/1800 kostenfrei https://doaj.org/toc/2076-393X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2023 12, p 1800 |
allfieldsGer |
10.3390/vaccines11121800 doi (DE-627)DOAJ098785818 (DE-599)DOAJ76032033a6d14d41b529d7176567df09 DE-627 ger DE-627 rakwb eng Ángela Domínguez verfasserin aut Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80.6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14.20; 95% CI 5.22–38.66) and exposure <6 h/day (aOR 7.32, 95% CI 2.48–21.64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0.22, 95% CI 0.08–0.64) and bacillus Calmette–Guerin vaccination (aOR 0.38, 95% CI 0.16–0.90). Crucial to LTBI treatment prescription is information on the contact’s duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels. contact tracing tuberculosis latent TB infection treatment prescription prevention Medicine R Núria Soldevila verfasserin aut Diana Toledo verfasserin aut Ignasi Parrón verfasserin aut Joan-Pau Millet verfasserin aut Irene Barrabeig verfasserin aut Pere Godoy verfasserin aut on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group verfasserin aut In Vaccines MDPI AG, 2013 11(2023), 12, p 1800 (DE-627)736559205 (DE-600)2703319-3 2076393X nnns volume:11 year:2023 number:12, p 1800 https://doi.org/10.3390/vaccines11121800 kostenfrei https://doaj.org/article/76032033a6d14d41b529d7176567df09 kostenfrei https://www.mdpi.com/2076-393X/11/12/1800 kostenfrei https://doaj.org/toc/2076-393X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2023 12, p 1800 |
allfieldsSound |
10.3390/vaccines11121800 doi (DE-627)DOAJ098785818 (DE-599)DOAJ76032033a6d14d41b529d7176567df09 DE-627 ger DE-627 rakwb eng Ángela Domínguez verfasserin aut Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80.6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14.20; 95% CI 5.22–38.66) and exposure <6 h/day (aOR 7.32, 95% CI 2.48–21.64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0.22, 95% CI 0.08–0.64) and bacillus Calmette–Guerin vaccination (aOR 0.38, 95% CI 0.16–0.90). Crucial to LTBI treatment prescription is information on the contact’s duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels. contact tracing tuberculosis latent TB infection treatment prescription prevention Medicine R Núria Soldevila verfasserin aut Diana Toledo verfasserin aut Ignasi Parrón verfasserin aut Joan-Pau Millet verfasserin aut Irene Barrabeig verfasserin aut Pere Godoy verfasserin aut on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group verfasserin aut In Vaccines MDPI AG, 2013 11(2023), 12, p 1800 (DE-627)736559205 (DE-600)2703319-3 2076393X nnns volume:11 year:2023 number:12, p 1800 https://doi.org/10.3390/vaccines11121800 kostenfrei https://doaj.org/article/76032033a6d14d41b529d7176567df09 kostenfrei https://www.mdpi.com/2076-393X/11/12/1800 kostenfrei https://doaj.org/toc/2076-393X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2023 12, p 1800 |
language |
English |
source |
In Vaccines 11(2023), 12, p 1800 volume:11 year:2023 number:12, p 1800 |
sourceStr |
In Vaccines 11(2023), 12, p 1800 volume:11 year:2023 number:12, p 1800 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
contact tracing tuberculosis latent TB infection treatment prescription prevention Medicine R |
isfreeaccess_bool |
true |
container_title |
Vaccines |
authorswithroles_txt_mv |
Ángela Domínguez @@aut@@ Núria Soldevila @@aut@@ Diana Toledo @@aut@@ Ignasi Parrón @@aut@@ Joan-Pau Millet @@aut@@ Irene Barrabeig @@aut@@ Pere Godoy @@aut@@ on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group @@aut@@ |
publishDateDaySort_date |
2023-01-01T00:00:00Z |
hierarchy_top_id |
736559205 |
id |
DOAJ098785818 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ098785818</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414002229.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/vaccines11121800</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ098785818</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ76032033a6d14d41b529d7176567df09</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ángela Domínguez</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80.6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14.20; 95% CI 5.22–38.66) and exposure <6 h/day (aOR 7.32, 95% CI 2.48–21.64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0.22, 95% CI 0.08–0.64) and bacillus Calmette–Guerin vaccination (aOR 0.38, 95% CI 0.16–0.90). Crucial to LTBI treatment prescription is information on the contact’s duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">contact tracing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tuberculosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">latent TB infection</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prescription</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prevention</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Núria Soldevila</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Diana Toledo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ignasi Parrón</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joan-Pau Millet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Irene Barrabeig</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pere Godoy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Vaccines</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">11(2023), 12, p 1800</subfield><subfield code="w">(DE-627)736559205</subfield><subfield code="w">(DE-600)2703319-3</subfield><subfield code="x">2076393X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:12, p 1800</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/vaccines11121800</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/76032033a6d14d41b529d7176567df09</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2076-393X/11/12/1800</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2076-393X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2023</subfield><subfield code="e">12, p 1800</subfield></datafield></record></collection>
|
author |
Ángela Domínguez |
spellingShingle |
Ángela Domínguez misc contact tracing misc tuberculosis misc latent TB infection misc treatment misc prescription misc prevention misc Medicine misc R Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study |
authorStr |
Ángela Domínguez |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)736559205 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
2076393X |
topic_title |
Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study contact tracing tuberculosis latent TB infection treatment prescription prevention |
topic |
misc contact tracing misc tuberculosis misc latent TB infection misc treatment misc prescription misc prevention misc Medicine misc R |
topic_unstemmed |
misc contact tracing misc tuberculosis misc latent TB infection misc treatment misc prescription misc prevention misc Medicine misc R |
topic_browse |
misc contact tracing misc tuberculosis misc latent TB infection misc treatment misc prescription misc prevention misc Medicine misc R |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Vaccines |
hierarchy_parent_id |
736559205 |
hierarchy_top_title |
Vaccines |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)736559205 (DE-600)2703319-3 |
title |
Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study |
ctrlnum |
(DE-627)DOAJ098785818 (DE-599)DOAJ76032033a6d14d41b529d7176567df09 |
title_full |
Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study |
author_sort |
Ángela Domínguez |
journal |
Vaccines |
journalStr |
Vaccines |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2023 |
contenttype_str_mv |
txt |
author_browse |
Ángela Domínguez Núria Soldevila Diana Toledo Ignasi Parrón Joan-Pau Millet Irene Barrabeig Pere Godoy on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group |
container_volume |
11 |
format_se |
Elektronische Aufsätze |
author-letter |
Ángela Domínguez |
doi_str_mv |
10.3390/vaccines11121800 |
author2-role |
verfasserin |
title_sort |
factors associated with treatment prescription to pulmonary tuberculosis contacts in catalonia (2019–2021): a population-based epidemiological study |
title_auth |
Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study |
abstract |
In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80.6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14.20; 95% CI 5.22–38.66) and exposure <6 h/day (aOR 7.32, 95% CI 2.48–21.64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0.22, 95% CI 0.08–0.64) and bacillus Calmette–Guerin vaccination (aOR 0.38, 95% CI 0.16–0.90). Crucial to LTBI treatment prescription is information on the contact’s duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels. |
abstractGer |
In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80.6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14.20; 95% CI 5.22–38.66) and exposure <6 h/day (aOR 7.32, 95% CI 2.48–21.64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0.22, 95% CI 0.08–0.64) and bacillus Calmette–Guerin vaccination (aOR 0.38, 95% CI 0.16–0.90). Crucial to LTBI treatment prescription is information on the contact’s duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels. |
abstract_unstemmed |
In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80.6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14.20; 95% CI 5.22–38.66) and exposure <6 h/day (aOR 7.32, 95% CI 2.48–21.64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0.22, 95% CI 0.08–0.64) and bacillus Calmette–Guerin vaccination (aOR 0.38, 95% CI 0.16–0.90). Crucial to LTBI treatment prescription is information on the contact’s duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
12, p 1800 |
title_short |
Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study |
url |
https://doi.org/10.3390/vaccines11121800 https://doaj.org/article/76032033a6d14d41b529d7176567df09 https://www.mdpi.com/2076-393X/11/12/1800 https://doaj.org/toc/2076-393X |
remote_bool |
true |
author2 |
Núria Soldevila Diana Toledo Ignasi Parrón Joan-Pau Millet Irene Barrabeig Pere Godoy on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group |
author2Str |
Núria Soldevila Diana Toledo Ignasi Parrón Joan-Pau Millet Irene Barrabeig Pere Godoy on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group |
ppnlink |
736559205 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3390/vaccines11121800 |
up_date |
2024-07-03T19:12:20.228Z |
_version_ |
1803586308912709632 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ098785818</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414002229.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/vaccines11121800</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ098785818</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ76032033a6d14d41b529d7176567df09</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ángela Domínguez</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Factors Associated with Treatment Prescription to Pulmonary Tuberculosis Contacts in Catalonia (2019–2021): A Population-Based Epidemiological Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In countries with low tuberculosis (TB) incidence, the systematic testing and treatment of latent TB infection (LTBI) in contacts of pulmonary TB index cases is the standard of care. The objective of this study, conducted in Catalonia over 2019–2021, was to assess the factors associated with LTBI treatment prescription to close contacts of pulmonary TB index cases. In this population-based epidemiological study of LTBI prevalence among pulmonary TB contacts between 2019 and 2021, multiple logistic backward stepwise regression was used to identify the factors associated with treatment prescription, for which the adjusted odds ratio (aOR) and 95% confidence intervals (CI) were calculated. A total of 1487 LTBI contacts of 542 pulmonary TB index cases were studied, 80.6% of whom received a prescription. The factors associated with LTBI treatment prescription were exposure ≥6 h/day (aOR 14.20; 95% CI 5.22–38.66) and exposure <6 h/day (aOR 7.32, 95% CI 2.48–21.64), whereas the factors associated with no LTBI treatment prescription were age ≥55 years (aOR 0.22, 95% CI 0.08–0.64) and bacillus Calmette–Guerin vaccination (aOR 0.38, 95% CI 0.16–0.90). Crucial to LTBI treatment prescription is information on the contact’s duration of exposure to pulmonary TB, not only for contacts exposed for ≥6 h/day, but also for contacts with lower daily exposure levels.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">contact tracing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tuberculosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">latent TB infection</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prescription</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prevention</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Núria Soldevila</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Diana Toledo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ignasi Parrón</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joan-Pau Millet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Irene Barrabeig</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pere Godoy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">on behalf of Transmission of Tuberculosis in Catalonia (Spain) Working Group</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Vaccines</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">11(2023), 12, p 1800</subfield><subfield code="w">(DE-627)736559205</subfield><subfield code="w">(DE-600)2703319-3</subfield><subfield code="x">2076393X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:12, p 1800</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/vaccines11121800</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/76032033a6d14d41b529d7176567df09</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2076-393X/11/12/1800</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2076-393X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2023</subfield><subfield code="e">12, p 1800</subfield></datafield></record></collection>
|
score |
7.399768 |